My ePortfolio Register   

Can we afford immunotherapy?

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.10.17
Views: 539

Dr Peter Hall - University of Edinburgh, Edinburgh, UK

Dr Hall speaks with ecancer at the ACP immunotherapy workshop about the barriers to immunotherapy availability through the NHS.

He describes the balance of incentivising drug development with paying for it out of taxpayer contributions, and differences between NICE and the Scottish Medicines Consortium.

For more on the approval and availability of drugs, watch a summary of cost and suitability measures here.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence